These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 18951461)

  • 1. Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications.
    Tavtigian SV; Byrnes GB; Goldgar DE; Thomas A
    Hum Mutat; 2008 Nov; 29(11):1342-54. PubMed ID: 18951461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of unclassified missense substitutions in human BRCA1.
    Tavtigian SV; Samollow PB; de Silva D; Thomas A
    Fam Cancer; 2006; 5(1):77-88. PubMed ID: 16528611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
    Tavtigian SV; Deffenbaugh AM; Yin L; Judkins T; Scholl T; Samollow PB; de Silva D; Zharkikh A; Thomas A
    J Med Genet; 2006 Apr; 43(4):295-305. PubMed ID: 16014699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico analysis of missense substitutions using sequence-alignment based methods.
    Tavtigian SV; Greenblatt MS; Lesueur F; Byrnes GB;
    Hum Mutat; 2008 Nov; 29(11):1327-36. PubMed ID: 18951440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.
    Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV
    Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods.
    Mathe E; Olivier M; Kato S; Ishioka C; Hainaut P; Tavtigian SV
    Nucleic Acids Res; 2006; 34(5):1317-25. PubMed ID: 16522644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation.
    Abkevich V; Zharkikh A; Deffenbaugh AM; Frank D; Chen Y; Shattuck D; Skolnick MH; Gutin A; Tavtigian SV
    J Med Genet; 2004 Jul; 41(7):492-507. PubMed ID: 15235020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multigene testing of moderate-risk genes: be mindful of the missense.
    Young EL; Feng BJ; Stark AW; Damiola F; Durand G; Forey N; Francy TC; Gammon A; Kohlmann WK; Kaphingst KA; McKay-Chopin S; Nguyen-Dumont T; Oliver J; Paquette AM; Pertesi M; Robinot N; Rosenthal JS; Vallee M; Voegele C; Hopper JL; Southey MC; Andrulis IL; John EM; Hashibe M; Gertz J; ; Le Calvez-Kelm F; Lesueur F; Goldgar DE; Tavtigian SV
    J Med Genet; 2016 Jun; 53(6):366-76. PubMed ID: 26787654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs.
    Vallée MP; Francy TC; Judkins MK; Babikyan D; Lesueur F; Gammon A; Goldgar DE; Couch FJ; Tavtigian SV
    Hum Mutat; 2012 Jan; 33(1):22-8. PubMed ID: 21990165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.
    Chenevix-Trench G; Healey S; Lakhani S; Waring P; Cummings M; Brinkworth R; Deffenbaugh AM; Burbidge LA; Pruss D; Judkins T; Scholl T; Bekessy A; Marsh A; Lovelock P; Wong M; Tesoriero A; Renard H; Southey M; Hopper JL; Yannoukakos K; Brown M; Easton D; Tavtigian SV; Goldgar D; Spurdle AB;
    Cancer Res; 2006 Feb; 66(4):2019-27. PubMed ID: 16489001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pitfalls and caveats in BRCA sequencing.
    Bellosillo B; Tusquets I
    Ultrastruct Pathol; 2006; 30(3):229-35. PubMed ID: 16825125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.
    Judkins T; Leclair B; Bowles K; Gutin N; Trost J; McCulloch J; Bhatnagar S; Murray A; Craft J; Wardell B; Bastian M; Mitchell J; Chen J; Tran T; Williams D; Potter J; Jammulapati S; Perry M; Morris B; Roa B; Timms K
    BMC Cancer; 2015 Apr; 15():215. PubMed ID: 25886519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput resequencing in the diagnosis of BRCA1/2 mutations using oligonucleotide resequencing microarrays.
    Schroeder C; Stutzmann F; Weber BH; Riess O; Bonin M
    Breast Cancer Res Treat; 2010 Jul; 122(1):287-97. PubMed ID: 19941162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New sequence variants in BRCA1 and BRCA2 genes detected by high-resolution melting analysis in an elderly healthy female population in Croatia.
    Cvok ML; Cretnik M; Musani V; Ozretic P; Levanat S
    Clin Chem Lab Med; 2008; 46(10):1376-83. PubMed ID: 18844490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
    J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
    Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
    Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
    Spurdle AB; Lakhani SR; Healey S; Parry S; Da Silva LM; Brinkworth R; Hopper JL; Brown MA; Babikyan D; Chenevix-Trench G; Tavtigian SV; Goldgar DE;
    J Clin Oncol; 2008 Apr; 26(10):1657-63. PubMed ID: 18375895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes.
    Cortesi L; Turchetti D; Bertoni C; Zanocco-Marani T; Vinceti M; Silvestri C; Federico M; Silingardi V; Ferrari S
    Eur J Hum Genet; 2003 Mar; 11(3):210-4. PubMed ID: 12673274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Genetic predisposition for breast cancer: BRCA1 and BRCA2 genes].
    Narod SA; Rodríguez AA
    Salud Publica Mex; 2011; 53(5):420-9. PubMed ID: 22218796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.